Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Cash & Equivalents (2017 - 2025)

Catheter Precision (VTAK) has disclosed Cash & Equivalents for 9 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 13.25% to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.1 million, a 13.25% decrease, with the full-year FY2024 number at $2.9 million, down 19.41% from a year prior.
  • Cash & Equivalents was $1.1 million for Q3 2025 at Catheter Precision, up from $838000.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $20.6 million in Q3 2021 to a low of $16000.0 in Q2 2024.
  • A 5-year average of $8.7 million and a median of $6.5 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 99.78% in 2024, then surged 5137.5% in 2025.
  • Catheter Precision's Cash & Equivalents stood at $15.0 million in 2021, then increased by 5.41% to $15.9 million in 2022, then tumbled by 77.52% to $3.6 million in 2023, then dropped by 19.41% to $2.9 million in 2024, then tumbled by 61.71% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Cash & Equivalents are $1.1 million (Q3 2025), $838000.0 (Q2 2025), and $500000.0 (Q1 2025).